Article Details

US FDA declines to approve AstraZeneca treatment for chronic nasal condition - Express Pharma

Retrieved on: 2022-03-15 12:26:42

Tags for this article:

Click the tags to see associated articles and topics

US FDA declines to approve AstraZeneca treatment for chronic nasal condition - Express Pharma. View article details on hiswai:

Excerpt

AstraZeneca Plc said yesterday the US drug regulator declined to approve its asthma medicine, Fasenra, for treatment of chronic rhinosinusitis ...

Article found on: www.expresspharma.in

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up